DW Top • May 6, 2026 14:42

BioNTech faces its biggest post pandemic crisis

Political Leaning Analysis

Left Center Right

Score: 0.00 • Center / Neutral

BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?

Story Timeline

Tue 10:48 - Die Welt

Biontech is closing several locations – more than 1,800 jobs affected

Tue 13:58 - DW All

Germany: BioNTech shutting down COVID vaccine production entirely, 1,860 jobs at risk

Tue 13:58 - DW Top

Germany: BioNTech shutting down COVID vaccine production entirely, 1,860 jobs at risk

Wed 08:52 - Tagesschau

Criticism of BioNTech's withdrawal from Germany

Wed 14:42 - DW All

BioNTech faces its biggest post pandemic crisis

Wed 14:42 - DW Top

BioNTech faces its biggest post pandemic crisis

Different Perspectives

DW All

2 articles

▼

14:42

BioNTech faces its biggest post pandemic crisis

13:58

Germany: BioNTech shutting down COVID vaccine production entirely, 1,860 jobs at risk

The German company that pioneered one of the first mRNA coronavirus vaccines is halting production, handing the reins to partner Pfizer. BioNTech is restructuring to focus on research and illnesses …

DW Top

1 article

▼

13:58

Germany: BioNTech shutting down COVID vaccine production entirely, 1,860 jobs at risk

Die Welt

1 article

▼

10:48

Biontech is closing several locations – more than 1,800 jobs affected

Werke, die wenig ausgelastet sind, Überkapazitäten in der Produktion, zudem müsse man dringend Kosten einsparen: So begründet der Impfstoffhersteller Biontech seine geplanten umfangreichen Stellenstreichungen.

Tagesschau

1 article

▼

08:52

Criticism of BioNTech's withdrawal from Germany

Nach der verkündeten Schließung der Produktionsstätten von BioNTech in Deutschland wird vor möglichen Engpässen gewarnt. Scharfe Kritik kommt auch vom CureVac-Gründer und der Gewerkschaft.